To date, most studies have evaluated the role of PPARγ in major metabolic organs such as liver, adipocytes, pancreas, or skeletal muscles (Ahmadian et al, 2013), leading to target PPARγ for the treatment of type 2 diabetes with the development of the thiazolidinedione (TZD) class of drugs (Lehmann et al, 1995). The gene discussed is PPARG; the disease is type 2 diabetes mellitus.